Multiple Oral Dose Safety, Tolerability And Pharmacokinetic Study Of PF-04287881 In Healthy Adult Subjects

NCT01026545

Last updated date
Study Location
Pfizer Investigational Site
New Haven, Connecticut, 06511, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Respiratory Tract Infections
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-55 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Volunteers willing and able to be confined to the Clinical Research Unit and comply with study schedule.

- Women of non-childbearing potential only.

- Japanese subjects must have 4 Japanese grandparents who were born in Japan.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Previous antibiotic use within 14 days prior to dosing.


- Use of antibiotics during hospitalization within 90 days prior to dosing.


- History of hypersensitivity to macrolides or ketolides.


- Presence of clinically significant eye conditions (other than corrective lenses).

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Respiratory Tract InfectionsCompliance And Safety Study In Children With Upper And Lower Respiratory Tract Infections NCT00939185
ALL GENDERS
1 Year+
years
MULTIPLE SITES
Respiratory Tract InfectionsA Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults NCT03529773
  1. Mobile, Alabama
  2. Coral Gables, Florida
  3. Orlando, Florida
  4. Stockbridge, Georgia
  5. Honolulu, Hawaii
  6. Saint Louis, Missouri
  7. Binghamton, New York
  8. Endwell, New York
  9. Charlotte, North Carolina
  10. Raleigh, North Carolina
  11. Wilmington, North Carolina
  12. Winston-Salem, North Carolina
  13. Cincinnati, Ohio
  14. Columbus, Ohio
  15. Dayton, Ohio
  16. Oklahoma City, Oklahoma
  17. Dakota Dunes, South Dakota
  18. Austin, Texas
  19. Austin, Texas
  20. Salt Lake City, Utah
  21. Salt Lake City, Utah
  22. South Jordan, Utah
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Respiratory Tract InfectionsSafety And Pharmacokinetics Study Of PF-04287881 In Healthy Adults NCT00793000
  1. New Haven, Connecticut
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Respiratory Tract InfectionsMultiple Oral Dose Safety, Tolerability And Pharmacokinetic Study Of PF-04287881 In Healthy Adult Subjects NCT01026545
  1. New Haven, Connecticut
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Multiple Oral Dose Safety, Tolerability And Pharmacokinetic Study Of PF-04287881 In Healthy Adult Subjects
Official Title  ICMJE A Phase 1, Double-Blind, Randomized, Placebo-Controlled Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-04287881 After Administration Of Multiple Escalating Oral Doses To Healthy Adult Subjects
Brief Summary

This study is a randomized, investigator blind, subject blind, sponsor-open, placebo controlled, multiple dose escalating, sequential, parallel cohort study of PF-04287881. Subjects will undergo screening procedures within 28 days prior to dosing. At least 1 day after the Screening visit, eligible subjects who meet the entry criteria will be admitted to the Clinical Research Unit (CRU) and confined in the unit until discharge on Day 15.

Approximately 60 healthy volunteers (20 volunteers of Japanese origin for Cohorts 5 and 6), 18 to 55 years of age, males and females (women of non childbearing potential only) will be enrolled and randomized in a 4:1 ratio to treatment with either PF-04287881 or placebo within each cohort. Each cohort will have a 10 day dosing period and each will consist of 10 subjects (8 active and 2 placebo). In each cohort, each subject will receive a single daily oral dose of either placebo or PF-04287881 under fasted state for 10 days.

Detailed Description Following a Serious Adverse Event (potential Hy's Law case), a risk-benefit assessment review of all preliminary safety data, and a review by Pfizer's internal hepatic injury advisory panel, it was concluded that PF-04287881 had an unacceptable therapeutic window. The FDA was notified of our intention to discontinue development as of 09April2010.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Condition  ICMJE Respiratory Tract Infections
Intervention  ICMJE
  • Drug: PF-04287881
    500 mg once daily for 10 days
  • Drug: Placebo
    To match 500 mg dose once daily for 10 days
  • Drug: PF-04287881
    750 mg once daily for 10 days
  • Drug: Placebo
    To match 750 mg dose once daily for 10 days
  • Drug: PF-04287881
    1100 mg once daily for 10 days
  • Drug: Placebo
    To match 1100 mg dose once daily for 10 days
  • Drug: PF-04287881
    Optional cohort with dose not greater than 1100 mg
  • Drug: Placebo
    Optional cohort to match dose not greater than 1100 mg
  • Drug: PF-04287881
    750 mg dose once daily for 10 days
  • Drug: PF-04287881
    1100 mg dose once daily for 10 days
Study Arms  ICMJE
  • Experimental: Cohort 1
    Interventions:
    • Drug: PF-04287881
    • Drug: Placebo
  • Experimental: Cohort 2
    Interventions:
    • Drug: PF-04287881
    • Drug: Placebo
  • Experimental: Cohort 3
    Interventions:
    • Drug: PF-04287881
    • Drug: Placebo
  • Experimental: Cohort 4 (optional)
    If intermediate or repeat dose level is needed; dose will not exceed 1100 mg.
    Interventions:
    • Drug: PF-04287881
    • Drug: Placebo
  • Experimental: Cohort 5 (Japanese)
    Interventions:
    • Drug: PF-04287881
    • Drug: Placebo
  • Experimental: Cohort 6 (Japanese)
    Interventions:
    • Drug: PF-04287881
    • Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 15, 2010)
39
Original Estimated Enrollment  ICMJE
 (submitted: December 3, 2009)
60
Actual Study Completion Date  ICMJE July 2010
Actual Primary Completion Date July 2010   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Volunteers willing and able to be confined to the Clinical Research Unit and comply with study schedule.
  • Women of non-childbearing potential only.
  • Japanese subjects must have 4 Japanese grandparents who were born in Japan.

Exclusion Criteria:

  • Previous antibiotic use within 14 days prior to dosing.
  • Use of antibiotics during hospitalization within 90 days prior to dosing.
  • History of hypersensitivity to macrolides or ketolides.
  • Presence of clinically significant eye conditions (other than corrective lenses).
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 55 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01026545
Other Study ID Numbers  ICMJE B0581002
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date May 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP